Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure Jan 9, 2014 7:00 am EST
First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology Oct 15, 2013 8:00 am EDT
Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer Sep 17, 2013 1:18 pm EDT
Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study Jul 30, 2013 7:00 am EDT
Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027 Jul 8, 2013 7:00 am EDT
Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure May 9, 2013 6:00 am EDT